2022 - Pharmacology of asthma and COPD: current and future developments

Pharmacological management of airway obstructive diseases is a fast evolving field. Several advances in unravelling disease mechanism as well as intracellular and molecular pathways of drug action have been accomplished. While the clinical translation and implementation of in vitro results at bedside remains challenging, advances in the comprehending of mechanisms of respiratory medication is expected to assist clinician-scientists in identifying meaningful read-outs and designing clinical studies. The crosstalk between basic, translational and clinical experts at all levels, including other stakeholders such as industry and patient representatives should align common needs and expectations. This research seminar focused on the current understanding of disease mechanisms and drug action and how the cooperation between basic, translational and clinical research can contribute to advance the field.

Objectives:

Understand the nature and mechanisms of actions of the curren

2022 - Pharmacology of asthma and COPD: current and future developments

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Understanding the mechanism of action of bronchodilators in asthma and COPD

Maria Gabriella Matera (Napoli, Italy)

Accompanying documents

How do inhaled steroids work and interact in asthma and COPD?

Maarten van den Berge (Groningen, Netherlands)

Accompanying documents

Biomarker guided pharmacological intervention

Daiana Stolz (Basel, Switzerland)

Accompanying documents

Do we understand remodeling in asthma and COPD?

Eleni Papakonstantinou (Basel, Switzerland)

Accompanying documents

Lung regeneration: is it still far from reality?

Reinoud Gosens (Groningen, Netherlands)

Accompanying documents

Emerging classes of drugs for the treatment of obstructive lung disease

Dave Singh (Manchester, United Kingdom)

Accompanying documents

Key challenges faced for approval of anti-inflammatory drugs for asthma and COPD - European Medicines Agency perspective

Laura Fregonese (London, United Kingdom)

Accompanying documents

New insights into steroid resistance

Nicola Hanania (Houston, United States)

Replay

Comorbidities and drug interactions

Mario Cazzola (Roma (RM), Italy)

Accompanying documents

Precision medicine in asthma, pharmacogenomics and beyond

Anke-Hilse Maitland-van der Zee (Amsterdam, Netherlands)

Accompanying documents

CDN Connection Issue

2022 - Pharmacology of asthma and COPD: current and future developments

2022 - Pharmacology of asthma and COPD: current and future developments

#{title}